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Background: Multiple sclerosis is generally considered an autoimmune disease resulting from interaction between
predisposing genes and environmental factors, together allowing immunological self-tolerance to be compromised.
The precise nature of the environmental inputs has been elusive, infectious agents having received considerable
attention. A recent study generated an algorithm predicting naturally occurring T cell receptor (TCR) ligands from the
proteome database. Taking the example of a multiple sclerosis patient-derived anti-myelin TCR, the study identified a
number of stimulatory, cross-reactive peptide sequences from environmental and human antigens. Having previously
generated a spontaneous multiple sclerosis (MS) model through expression of this TCR, we asked whether any of these
could indeed function in vivo to trigger CNS disease by cross-reactive activation.
Findings: A number of myelin epitope cross-reactive epitopes could stimulate T cell immunity in this MS anti-myelin TCR
transgenic model. Two of the most stimulatory of these ‘environmental’ epitopes, from Dictyostyelium slime mold and
from Emiliania huxleyi, were tested for the ability to induce MS-like disease in the transgenics. We found that immunization
with cross-reactive peptide from Dictyostyelium slime mold (but not from E. huxleyi) induces severe disease.
Conclusions: These specific environmental epitopes are unlikely to be common triggers of MS, but this study suggests
that our search for the cross-reactivity triggers of autoimmune activation leading to MS should encompass epitopes not
just from the ‘infectome’ but also from the full environmental ‘exposome.’
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ExposomeFindings
For multiple sclerosis (MS), as with other autoimmune dis-
eases, susceptibility depends to some extent on a number
of predisposing genes, disease being conferred to a greater
degree by uncharted environmental risk factors [1]. The im-
pact of environmental risk factors is inferred, for example,
from many studies showing that migration as a child from
a country of low prevalence to a country of high prevalence
imposes the risk of the new country of domicile [2]. Epi-
demiological studies aimed at characterizing the environ-
mental determinants have been challenging. Those that
have received the most attention are UV-exposure and in-
fectious history [3]. Of the many infectious agents that have* Correspondence: r.boyton@imperial.ac.uk
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unless otherwise stated.been considered, Epstein-Barr virus (EBV) is arguably the
pathogen for which there is most supporting evidence, in-
cluding evidence from the relationship between severe
infectious mononucleosis and MS [4]. The case for a mi-
crobial pathogen in etiology has been argued in relation ei-
ther to cross-reactive stimulation of autoreactive T cell
receptors by related pathogen sequences (molecular mim-
icry) or to pathogen-driven CNS inflammation and by-
stander activation [5,6].
A recent study used deep-sequencing data and proteomic
databases to generate an algorithm for naturally occurring T
cell receptor (TCR) ligands [7]. This encompassed a search
for naturally occurring, cross-reactive, environmental ligands
for a prototypic, multiple sclerosis patient-derived T cell re-
ceptor specific for myelin basic protein epitope. An implica-
tion was that in autoimmune etiology, we may now need to
consider not just pathogen exposure but all of the structur-
ally related potentially cross-reactive protein-derived ligandsal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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some in its broadest sense [8].
Hypothesis
Having previously reported modeling of MS immunology
and pathology in an HLA-DR15 and TCR transgenic
model utilizing the same myelin basic protein (MBP) spe-
cific TCR as used by Birnbaum et al. [9], we, here, took
the opportunity to investigate whether ‘environmental’
peptides implicated by the structural algorithm could in-
deed act by cross-reactivity to induce disease.
In the model that we have previously reported, expression
of the Ob1.A12 TCR on a high proportion of murine CD4
and CD8 cells results in spontaneous, chronic demyelinat-
ing disease, highly reminiscent of human MS [9,10]. This
strain, termed Line 7, shows disease that is initially medi-
ated by migration to the CNS of IFNγ-secreting and then
IL-17-secreting cells and encompasses intermolecular epi-
tope spread from the initial MBP 85-99 epitope. While
spontaneous disease can develop at any stage from around
16 weeks to 1 year or older, synchronous disease can be in-
duced in young-adult mice by the injection of MBP peptide
in adjuvant.
Methods
Line 7 mice have been previously described by us and
carry HLA-DR15 with an anti-MBP (85-99)-specific TCR
(clone Ob1.A12) on an Aβo background [9,10]. Mice were
maintained in individually ventilated cages and were used
in experiments as age- and sex-matched young adults.
Mouse experiments were performed within UK Home Of-
fice legislation under the terms of the Project License PPL
70/8110 granted for this work under the ‘Animals (Scien-
tific Procedures) Act 1986’. Local ethical review andTable 1 Peptide sequence and origin
Peptide sequencea Mr # Species
ENPVVHFFKNIVTP 1641 MBP Homo sapien
FGVKIHFFKQRNSL 1721 A Encephalitozoo
VFGNVHFFKNTGSA 1525 B Chlorobium chl
AAQRIHFFKNLSLL 1658 C Rhodococcus sp
LNKNIHFFKNLPLP 1695 D Clostridium pap
RLSVVHFLRANAVS 1569 E Anoxybacillus fl
AAQNVHFWKALNQL 1640 F Macrophomina
STARVHFWRSRSSE 1706 G Emiliania huxle
DVSKVHFFKGNGQT 1564 H Rhizobium legu
HRAKLHFFKDENLK 1783 I Runella slithyfo
YKHKIHFFKNEVLE 1832 J Dictyostelium fa
IEAAIHFYKGLAVY 1595 K Ogataea parap
SSARLHFFRALPHP 1636 L Myxococcus stip
KDFTFVCPTEIVEFAKLAKQ 2315 Bp Burkholderia ps
aBold type face indicates sequence homology with MBP85-99..Data in this table are bformal approval had also been obtained through the Im-
perial College Ethical Review Process Committee.
Unprimed splenocytes from previously described Line 7
HLA-DR15 and TCR transgenics carrying an anti-MBP
(85-99)-specific TCR (clone Ob1.A12) on an HLA-
DR1501/Aβo background (n = 6) were cultured in triplicate
on pre-coated IFNγ ELISpot plates with 0.25, 2.5, or 25 μg/
ml of each of the 12 test peptides, MPB 85-99, and a nega-
tive control peptide (Burkholderia pseudomallei AhpC,
BPSL2096 51-70 KDFTFVCPTEIVEFAKLAKQ which
stimulates potent CD4 T cell responses in HLA-DR1501/
Aβo transgenic mice [11]). Cells were cultured for 72 h.
Data are expressed as SFC/106 splenocytes and shown as
mean values ± SEM.
Line 7 mice were used to test the encephalitogenic cap-
acity of test peptides. Young male mice received 300 μg
peptide subcutaneously in the flank using CFA supple-
mented with Mycobacterium butyricum at day 0 and 50
μg peptide subcutaneously in CFA at day 6. Pertussis toxin
at a dose of 200 ng intraperitoneally was administered on
days 0, 2, 6, and 8. Mice were scored daily for signs of
neurological disease using an established disease score
scale according to the following criteria: 0, normal; 1, limp
tail; 2, impaired righting reflex or waddling gait; 3, partial
hind limb paralysis; 4, total hind limb paralysis; 5, total
limb paralysis.Results
We started by reappraising in functional T cell assays
the relative functional avidity of the environmental
ligands described by Birnbaum et al. [7]. These encom-
passed peptide sequences from Encephalitozoon romaleae,
Chlorobium chlorochromatii, Rhodococcus sp. AW25MO9,Protein of origin
s Myelin basic protein (85-99)
n romaleae UDP-N-Acetylglucosamine pyrophosphorylase
orochromate CaD3 Hypothetical protein
. AW25m09 Hypothetical protein
yrosolvens Exonuclease ABC C subunit domain protein
avithermus Spore germination protein




sciculatum Hypothetical protein DFA
olymorpha Component of TOM complex
itatus Hypothetical protein
eudomallei AhpC (51-70)
ased on information within reference 7.
Figure 1 T cell assays show the relative functional avidity of environmental ligands. (A-L) Unprimed splenocytes from previously described HLA-DR15 and
TCR transgenics carrying an anti-MBP (85-99) specific TCR (clone Ob1.A12) on an HLA-DR1501/Aβo background (n = 6) were cultured in triplicate on
precoated IFNγ ELISpot plates with 0.25, 2.5, or 25 μg/ml of each of the 12 test peptides, MPB 85-99, and a negative control peptide (HLA-DR1501 binding
peptide from Burkholderia pseudomallei, AhpC, BPSL2096 (51-70) KDFTFVCPTEIVEFAKLAKQ which stimulates potent CD4 T cell responses in HLA-DR1501/Aβo
transgenic mice [11]). Cells were cultured for 72 h before plate development. Data are expressed as SFC/106 splenocytes and shown as mean values ± SEM.
In each case, MBP 85-99 positive control peptide is indicated as closed squares, test peptide as closed circles, and negative control peptide as closed triangles.
Test peptide identities were as follows: (A) Encephalitozoon romaleae, FGVKIHFFKQRNSL; (B) Chlorobium chlorochromatii CaD3, VFGNVHFFKNTGSA;
(C) Rhodococcus sp. AW25MO9, AAQRIHFFKNLSLL; (D) Clostridium papyrosolvens, LNKNIHFFKNLPLP; (E) Anoxybacillus flavithermus, RLSVVHFLRANAVS;
(F) Macrophomina phaseolina MS6, AAQNVHFWKALNQL; (G) Emiliania huxleyi CCMP1516, STARVHFWRSRSSE; (H) Rhizobium leguminosarum,
DVSKVHFFKGNGQT; (I) Runella slithyformis DSM 19594, HRAKLHFFKDENLK; (J) Dictyostelium fasciculatum, YKHKIHFFKNEVLE; (K) Ogataea parapolymorpha
DL-1, IEAAIHFYKGLAVY; (L) Myxococcus stipitatus DSM14675, SSARLHFFRALPHP.
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C57BL/6 control peptide, Burkholderia pseudomallei AhpC 51-70
Figure 2 Induction of autoimmune paralysis in TCR transgenic multiple
sclerosis model by a cross-reactive Dictyostelium slime mold peptide.
Previously described HLA-DR15 and TCR transgenics carrying an anti-MBP
(85-99) specific TCR (clone Ob1.A12) and HLA-DR1501, Ao were used to
test the encephalitogenic capacity of test peptides. Young male mice
received 300 μg peptide subcutaneously in supplemented CFA at day 0
and 50 μg peptide subcutaneously in CFA at day 6. Pertussis toxin at a
dose of 200 ng intraperitoneally was administered on days 0, 2, 6, and 8.
Mice were scored daily for signs of neurological disease using an
established disease score scale according to the following criteria: 0,
normal; 1, limp tail; 2, impaired righting reflex or waddling gait; 3, partial
hind limb paralysis; 4, total hind limb paralysis; 5, total limb paralysis.
HLA-DR15 and TCR transgenics carrying the anti-MBP (85-99)-specific
TCR (clone Ob1.A12) and HLA-DR1501, Ao were administered MBP 85-99
peptide (closed circles, n = 6), Dictyostelium fasciculatum YKHKIHFFK
NEVLE peptide (closed squares, n = 6), Emiliania huxleyi CCMP1516
STARVHFWRSRSSE peptide (closed triangles, n = 6), control peptide,
Burkholderia pseudomallei AhpC (51-70) KDFTFVCPTEIVEFAKLAKQ (closed
diamonds, n = 6), C57BL/6 mice administered MBP 85-99 peptide
(open circles, n = 5), Emiliania huxleyi CCMP1516 STARVHFWRS
RSSE peptide (open triangles, n = 5), Dictyostelium fasciculatum
YKHKIHFFKNEVLE peptide (open squares, n = 5), and Burkholderia
pseudomallei AhpC (51-70) KDFTFVCPTEIVEFAKLAKQ (open
diamonds, n = 5). MBP, myelin basic protein.
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Macrophomina phaseolina, Emiliania huxleyi, Rhizobium
leguminosarum, Runella slithyformis, Dictyostelium fasci-
culatum, Ogataea parapolymorpha, and Myxococcus stipi-
tatus (Table 1). Screening Line 7 splenocytes, IFNγ
responses from unprimed mice, we observed a spectrum
of response to the epitopes that had been previously iden-
tified as cross-reactive for this receptor (Figure 1). Two
epitopes, from E. romaleae and from C. papyrosolvens
elicited virtually no T cell response. Most peptides yielded
a response that was significant but with reduced potency
of at least 100-fold relative to the wild-type MBP 85-99
peptide. Two of the peptides, from hypothetical proteins
of D. fasciculatum and E. huxleyi, induced responses
within 1-log of the MBP epitope. D. fasciculatum is a cel-
lular slime mold while E. huxleyi is a photosynthetic ocean
plankton. It is uncertain why some of those epitopes pre-
dicted to be stimulatory did not elicit a response in our
line 7 transgenics. However, even among lines expressing
the same human TCR pair, there will be differences in
response profile, determined for example by founder-
specific differences in TCR transgene expression.
Of the peptides that had induced cross-reactive T cell
responses in the line 7 mice, we tested the two most
stimulatory, from D. fasciculatum and from E. huxleyi, for
the ability to induce disease. These were compared to
MBP 85-99 peptide as a positive control and to an HLA-
DR15-binding CD4 T cell epitope from Burkholderia as a
negative control [11]. The Dictyostyelium slime mold epi-
tope could indeed induce severe disease (Figure 2). Paraly-
sis was of a time-course and severity similar to that
induced by MBP 85-99. Postmortem neuropathology was
not undertaken in this study, but our previous published
work has correlated the neurological disease score used
here with neuropathology (9,10). The ability to induce dis-
ease using environmental antigen-derived sequences was
not a simple correlate of functional avidity, since the simi-
larly stimulatory sequence from E. huxleyi did not induce
disease. Further work will be required to dissect the
underlying mechanism for this difference, which may re-
late to divergence in the cytokine profiles elicited.
Interpretation
To be clear, we interpret this as proof of principle rather
than specific evidence that exposure to slime mold se-
quences are pathogenic in clinical MS: the Ob1.A12 TCR
stimulated by this peptide is not a public receptor across
MS patients in general, and therefore, one would not
generalize a case based on its specific cross-reactivities.
Sequencing of the TCR repertoire from MS patients has
demonstrated substantial diversity in myelin epitope-specific
disease-implicated receptors [12,13]. Clearly, a further caveat
in considering the implications of environmental cross-
reactivities is that of predicted epitopes; not all could actuallystimulate T cells in our model, and not all peptides that
could stimulate could induce disease. Notwithstanding these
caveats and following on from the cross-reactivities modeled
by Birnbaum and colleagues and our subsequent demon-
stration that at least one example from an antigen in the
wider environment can trigger MS-like disease, we can con-
sider a new chapter of autoimmunity research, analyzing
such triggers and their contribution to disease. This newly
places the experimental analysis of the relationship between
an individual’s exposome, their immune repertoire, and their
susceptibility to autoimmunity within the domain of struc-
tural and functional immunology [14].
It has long been a given in MS research that there are
environmental risk factors relating to geography and, in par-
ticular, latitude [http://www.msif.org/wp-content/uploads/
Reynolds et al. Journal of Neuroinflammation  (2015) 12:91 Page 5 of 52014/09/Atlas-of-MS.pdf]. The implication of the model de-
scribed here is that it will now be important to consider in
this context not just old favorite candidate environmental
influences such as vitamin D exposure but also local flora
and fauna in its widest sense.
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